Neurogene

Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates on the bottom line, with a GAAP net loss of $34.5M vs. the $31.9M expected. GAAP EPS of -$1.55 missed the mean estimate of -$1.42, driven by higher-than-expected R&D and G&A expenses due to NGN-401 clinical activities and stock-based compensation. However, the company significantly strengthened its balance sheet via a $144M offering, extending its cash runway into Q1 2029, while reporting positive Phase 1/2 clinical data for Rett syndrome.